Drugs / IASO207
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT07574346 | May 2026 → Apr 2029 expected | cancer | Peking University People's Hospital | Recruiting | No outcome recorded |
| Phase 0 | NCT07617740 | May 2026 → May 2029 expected | systemic lupus erythematosus | Peking University People's Hospital | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IASO207 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07617740 ↗ |
| Target | CD19 | “a second-generation anti-human CD19 chimeric antigen receptor (CD19 CAR)” NCT07617740 ↗ |